entrectinib;N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide | |
---|---|
Trade Name | |
Orphan Indication | Neuroblastoma |
USA Market Approval | USA |
USA Designation Date | 2014-12-22 00:00:00 |
Sponsor | Ignyta, Inc.;4545 Towne Centre Court;San Diego, California, 92121 |
Related Access Program
South Plains Oncology Consortium – Recurrent Neuroblastoma
Catalyst Pharmaceuticals, Inc. – Downbeat Nystagmus
South Plains Oncology Consortium – Neuroblastoma
British Columbia Cancer Agency – Neuroblastoma
South Plains Oncology Consortium – Neuroblastoma
Children’s Hospital of Philadelphia – Neuroblastoma
University of California, San Francisco – Neuroblastoma
Jubilant DraxImage Inc. – Neuroblastoma
Children’s Hospital Medical Center, Cincinnati – Neuroblastoma
Apeiron Biologics AG – Neuroblastoma